US Edition
Published • loading... • Updated
Ziyang Zhang, PhD | Damon Runyon Cancer Research Foundation
Summary by Damon Runyon
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Ziyang Zhang, PhD | Damon Runyon Cancer Research Foundation
Ziyang Zhang, PhD Thu, 02/19/2026 - 17:52 Project title “Chemical stimulation of GTP hydrolysis for oncogenic Ras mutants and beyond” Dr. Zhang is developing a new form of cancer immunotherapy with improved safety and controllability. Redirecting the immune system to launch attacks on tumor cells has emerged as an extremely promising approach to fight cancer. One such strategy, named bispecific T cell engager antibody (BiTE) has shown remarka…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
